E. Cheng - Department of Gastroenterology, AbbVie Inc

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme

Tim Raine,Yoh Ishiguro,David T. Rubin,Tricia Finney-Hayward,Ramona Vladea,John Liu,Charles Phillips,Erica Cheng,Laura Targownik,Edward Loftus Jr

JOURNAL OF CROHNS & COLITISno. 5 (2024): 695-707

引用0浏览0WOS引用

Efficacy and Safety of Risankizumab by Baseline Corticosteroid Use and Achievement of Corticosteroid-Free Clinical and Endoscopic Outcomes in Patients with Moderately to Severely Active Crohn's Disease

Stefan Schreiber,Raymond K. Cross,Remo Panaccione,Geert D'Haens,Peter Bossuyt,Iris Dotan,Jean-Frederic Colombel,Edouard Louis,Marla C. Dubinsky,Kristina Kligys,Ezequiel Neimark,Alexandra Song,Javier Zambrano,Jasmina Kalabic,Erica Cheng,Yafei Zhang,Marc Ferrante

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2024)

引用0浏览0WOS引用

A107 VISCERAL ADIPOSE TISSUE VOLUME DIFFERENTIATES BETWEEN FIBROSTENOTIC AND INFLAMMATORY CROHN’S DISEASE

R Rosentreter,E Cheng, H Shen,C Ma, D Bhayana,R Panaccione,M Raman,A Medellin, C Lu

Journal of the Canadian Association of Gastroenterologyno. Supplement_1 (2023): 58-58

引用0浏览0引用

DOP40 Impact of Corticosteroid Usage on Efficacy and Safety Outcomes in Patients Receiving Upadacitinib for Ulcerative Colitis

Tim Raine,Yoh Ishiguro,David T. Rubin,Tricia K. Finney-Hayward,Dapo Ilo,Charles Philips,Erica Chong,Laura E. Targownik,Edward V. Loftus

Journal of Crohn s and Colitisno. Supplement_1 (2022): i089-i090

引用1浏览0引用

DOP82 Achievement of Steroid-Free Remission in Patients with Moderately to Severely Active Crohn’s Disease During Treatment with Risankizumab

Stefan Schreiber,Raymond K. Cross,Remo Panaccione,Geert D'Haens,Peter Bossuyt,Jean Frederic Colombel,Edouard Louis,Marla Dubinsky,Kristina Kligys,Ezequiel Neimark,Alexandra P. Song,Javier A. Zambrano,Erica Cheng,Marc Ferrante

Journal of Crohn s and Colitis（2022）

引用1浏览0引用

DOP83 Normalisation of Biomarkers and Improvement in Clinical Outcomes in Patients with Crohn’s Disease Treated with Risankizumab in the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

R. Atreya,B. Feagan, O. Shchukina,V. Jairath,F. Rieder,T. Hisamatsu,B. Siegmund, J. Rizzo,K. Kligys,E. Neimark,A. Song,J. Zambrano,M. Mallick,E. Cheng,A. Armuzzi

Journal of Crohn s and Colitis（2022）

引用1浏览0引用

Tu1451: ACHIEVEMENT OF STEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE DURING TREATMENT WITH RISANKIZUMAB

Gastroenterologyno. 7 (2022): S-966

引用0浏览0引用

Tu1448: EFFECT OF BASELINE DISEASE CHARACTERISTICS ON CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM A PHASE 3 TRIALS PROGRAMME

P. Higgins,J. F. Colombel, M. Reguiero,G. Parkes,D. Ilo,C. Philips,X. Yao,E. Cheng,S. Schreiber

Journal of Crohn s and Colitis（2022）

引用5浏览0引用

Tu1479: NORMALISATION OF BIOMARKERS AND IMPROVEMENT IN CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE TREATED WITH RISANKIZUMAB IN THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Raja Atreya,Brian G. Feagan,Oksana Shchukina,Vipul Jairath,Florian Rieder,Tadakazu Hisamatsu,Britta Siegmund,Joanne Rizzo,Kristina Kligys,Ezequiel Neimark,Alexandra P. Song,Javier A. Zambrano,Madhuja Mallick,Erica Cheng,Alessandro Armuzzi

Gastroenterologyno. 7 (2022): S-979

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn